Noveome Biotherapeutics, Inc. To Present At The 8thAnnual Neurodegenerative Drug Development Summit.
PITTSBURGH, PA–February 24, 2020 – Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced that Larry Brown, Sc.D., Executive Vice President and Chief Scientific Officer at Noveome, will present an oral presentation entitled, “Exploring Intranasal Administration to Bypass the Blood-Brain Barrier” at the 8thAnnual Neurodegenerative Drug Development Summit on Thursday February 27, 2020 at 11:15 AM EDT in Boston, MA.
About ST266
ST266 is a cell-free platform biologic containing hundreds of proteins and other factors in physiologic levels that are involved in cellular healing, protection of the brain and nerves, and modulation of inflammation. ST266 is the first potential therapeutic focused on treating the underlying nerve degeneration that occurs in glaucoma and optic nerve diseases and injuries through an innovative, non-invasive, targeted intranasal device to deliver ST266 directly to the retina and optic nerve by-passing the blood-brain barrier. Based on successful preclinical studies, Noveome is currently conducting a Phase 1 open-label clinical trial to establish the safety of ST266 in subjects with elevated ocular hypertension by intranasal deliverywith topline data expected in 2020.
About Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Its novel platform biologic, ST266, is currently being evaluated in multiple ophthalmic indications including aPhase 1 open label clinical trial to establish the safety of ST266 when deliveredintranasally to Glaucoma Suspects and a Phase 2 open-label clinical trial evaluating the efficacy of ST266 in healing persistent Corneal Epithelial Defects (PEDs). To date, Noveome has received over $160 million in research and infrastructure funding. Noveome is based in Pittsburgh, PA. For more information, please visit, www.noveome.com.
###
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com